5
Participants
Start Date
April 15, 2021
Primary Completion Date
February 1, 2024
Study Completion Date
February 1, 2024
Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide)
This study is conducted as open label, with each patient's response determined with an adaptive Bayesian model based on historical and baseline values for the primary endpoints of the trial. 3 monthly dose escalation steps will assess the efficacy of senicapoc in a dose range (10-40 mg/day) which has been used in prior trials for other indications.
Boston Children's Hospital, Boston
Boston Children's Hospital
OTHER